Table of Content

1 Key Insights

2 Executive Summary

3 SWOT Analysis

4 Non-muscle Invasive Bladder Cancer (NMIBC) Market Overview at a Glance
4.1 Patient Share (%) Distribution of Non-muscle Invasive Bladder Cancer (NMIBC) in 2017
4.2 Patient Share (%) Distribution of Non-muscle Invasive Bladder Cancer (NMIBC) in 2030

5 Disease Background and Overview: Non-muscle Invasive Bladder Cancer (NMIBC)
5.1 Introduction
5.2 Clinical Stages of NMIBC
5.3 Classification of NMIBC
5.4 TNM staging of NMIBC
5.5 Diagnosis of NMIBC
5.5.1 Cystoscopy
5.5.2 Urinary cytology – urinary molecular marker tests
5.5.3 Imaging
5.5.4 Rigid cystoscopy
5.6 European Association of Urology (EAU) Guidelines for Diagnosis of NMIBC
5.6.1 Signs and symptoms
5.6.2 Imaging
5.6.3 Urinary cytology
5.6.4 Urinary molecular marker tests
5.6.5 The potential application of urinary cytology and markers
5.6.6 Cystoscopy
5.6.7 Transurethral resection of TaT1 bladder tumors
5.6.8 New methods of tumor visualization
5.6.9 Second resection
5.6.10 Pathology report
5.7 Predictive Markers of NMIBC
5.7.1 Current markers
5.7.2 Prognostic Biomarkers
5.7.3 Predictive Biomarkers for BCG response

6 Recognized Establishments

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Epidemiology Methodology

8 7MM Total Diagnosed Prevalent cases of Non-muscle Invasive Bladder (NMIBC)

9 7MM Epidemiology of Non-muscle Invasive Bladder Cancer (NMIBC)
9.1 Assumption and Rationale
9.1 United States
9.1.1 Prevalent cases of Bladder Cancer in the United States
9.1.2 Diagnosed Prevalent cases of Bladder Cancer in the United States
9.1.3 Diagnosed Prevalent cases of NMIBC in the United States
9.1.4 Age-specific Diagnosed Prevalence of NMIBC in the United States
9.1.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States
9.1.6 Grade-specific Diagnosed Prevalence of NMIBC in the United States
9.1.7 Risk-specific Diagnosed Prevalence of NMIBC in the United States
9.2 EU5 Countries
9.3 Germany
9.3.1 Prevalent cases of Bladder Cancer in Germany
9.3.2 Diagnosed Prevalent cases of Bladder Cancer in Germany
9.3.3 Diagnosed Prevalent cases of NMIBC in Germany
9.3.4 Age-specific Diagnosed Prevalence of NMIBC in Germany
9.3.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany
9.3.6 Grade-specific Diagnosed Prevalence of NMIBC in Germany
9.3.7 Risk-specific Diagnosed Prevalence of NMIBC in Germany
9.4 France
9.4.1 Prevalent cases of Bladder Cancer in France
9.4.2 Diagnosed Prevalent cases of Bladder Cancer in France
9.4.3 Diagnosed Prevalent cases of NMIBC in France
9.4.4 Age-specific Diagnosed Prevalence of NMIBC in France
9.4.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France
9.4.6 Grade-specific Diagnosed Prevalence of NMIBC in France
9.4.7 Risk-specific Diagnosed Prevalence of NMIBC in France
9.5 Italy
9.5.1 Prevalent cases of Bladder Cancer in Italy
9.5.2 Diagnosed Prevalent cases of Bladder Cancer in Italy
9.5.3 Diagnosed Prevalent cases of NMIBC in Italy
9.5.4 Age-specific Diagnosed Prevalence of NMIBC in Italy
9.5.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Italy
9.5.6 Grade-specific Diagnosed Prevalence of NMIBC in Italy
9.5.7 Risk-specific Diagnosed Prevalence of NMIBC in Italy
9.6 Spain
9.6.1 Prevalent cases of Bladder Cancer in Spain
9.6.2 Diagnosed Prevalent cases of Bladder Cancer in Spain
9.6.3 Diagnosed Prevalent cases of NMIBC in Spain
9.6.4 Age-specific Diagnosed Prevalence of NMIBC in Spain
9.6.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain
9.6.6 Grade-specific Diagnosed Prevalence of NMIBC in Spain
9.6.7 Risk-specific Diagnosed Prevalence of NMIBC in Spain
9.7 United Kingdom
9.7.1 Prevalent cases of Bladder Cancer in the United Kingdom
9.7.2 Diagnosed Prevalent cases of Bladder Cancer in the United Kingdom
9.7.3 Diagnosed Prevalent cases of NMIBC in the United Kingdom
9.7.4 Age-specific Diagnosed Prevalence of NMIBC in the United Kingdom
9.7.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United Kingdom
9.7.6 Grade-specific Diagnosed Prevalence of NMIBC in the United Kingdom
9.7.7 Risk-specific Diagnosed Prevalence of NMIBC in the United Kingdom
9.8 Japan
9.8.1 Prevalent cases of Bladder Cancer in Japan
9.8.2 Diagnosed Prevalent cases of Bladder Cancer in Japan
9.8.3 Diagnosed Prevalent cases of NMIBC in Japan
9.8.4 Age-specific Diagnosed Prevalence of NMIBC in Japan
9.8.5 Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan
9.8.6 Grade-specific Diagnosed Prevalence of NMIBC in Japan
9.8.7 Risk-specific Diagnosed Prevalence of NMIBC in Japan

10 Appendix

11 DelveInsight Capabilities

12 Disclaimer

13 About DelveInsight



List of Figures


Figure 1: SWOT Analysis of Non-muscle Invasive Bladder Cancer
Figure 2: Stages of Bladder Cancer
Figure 3: Different stages of NMIBC
Figure 4: Visualization of potential prognostic and predictive biomarkers in MIBC
Figure 5: Total Diagnosed Prevalent cases of NMIBC in the 7MM (2017–2030)
Figure 6: Prevalent cases of Bladder Cancer in the United States (2017–2030)
Figure 7: Diagnosed Prevalent cases of Bladder Cancer in the United States (2017–2030)
Figure 8: Diagnosed Prevalent cases of NMIBC in the United States (2017–2030)
Figure 9: Age-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Figure 10: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Figure 11: Grade-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Figure 12: Risk-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Figure 13: Prevalent cases of Bladder Cancer in Germany (2017–2030)
Figure 14: Diagnosed Prevalent cases of Bladder Cancer in Germany (2017–2030)
Figure 15: Diagnosed Prevalent cases of NMIBC in Germany (2017–2030)
Figure 16: Age-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Figure 17: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Figure 18: Grade-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Figure 19: Risk-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Figure 20: Prevalent cases of Bladder Cancer in France (2017–2030)
Figure 21: Diagnosed Prevalent cases of Bladder Cancer in France (2017–2030)
Figure 22: Diagnosed Prevalent cases of NMIBC in France (2017–2030)
Figure 23: Age-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Figure 24: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Figure 25: Grade-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Figure 26: Risk-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Figure 27: Prevalent cases of Bladder Cancer in Italy (2017–2030)
Figure 28: Diagnosed Prevalent cases of Bladder Cancer in Italy (2017–2030)
Figure 29: Diagnosed Prevalent cases of NMIBC in Italy (2017–2030)
Figure 30: Age-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Figure 31: Tumor (T) stage specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Figure 32: Grade-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Figure 33: Risk-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Figure 34: Prevalent cases of Bladder Cancer in Spain (2017–2030)
Figure 35: Diagnosed Prevalent cases of Bladder Cancer in Spain (2017–2030)
Figure 36: Diagnosed Prevalent cases of NMIBC in Spain (2017–2030)
Figure 37: Age-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Figure 38: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Figure 39: Grade-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Figure 40: Risk-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Figure 41: Prevalent cases of Bladder Cancer in the United Kingdom (2017–2030)
Figure 42: Diagnosed Prevalent cases of Bladder Cancer in the UK (2017–2030)
Figure 43: Diagnosed Prevalent cases of NMIBC in the UK (2017–2030)
Figure 44: Age-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Figure 45: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Figure 46: Grade-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Figure 47: Risk-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Figure 48: Prevalent cases of Bladder Cancer in Japan (2017–2030)
Figure 49: Diagnosed Prevalent cases of Bladder Cancer in Japan (2017–2030)
Figure 50: Diagnosed Prevalent cases of NMIBC in Japan (2017–2030)
Figure 51: Age-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Figure 52: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Figure 53: Grade-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Figure 54: Risk-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)


List of Tables


Table 1: Summary of Non-muscle invasive bladder cancer (NMIBC), Epidemiology, and Key Events (2017–2030)
Table 2: Sub-grouping of the non-invasive urothelial neoplasms with an inverted growth pattern
Table 3: Summary of more established urinary markers
Table 4: Total Diagnosed Prevalent cases of NMIBC in the 7MM (2017–2030)
Table 5: Prevalent cases of Bladder Cancer in the United States (2017–2030)
Table 6: Diagnosed Prevalent cases of Bladder Cancer in the United States (2017–2030)
Table 7: Diagnosed Prevalent cases of NMIBC in the United States (2017–2030)
Table 8: Age-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Table 9: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Table 10: Grade-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Table 11: Risk-specific Diagnosed Prevalence of NMIBC in the United States (2017–2030)
Table 12: Prevalent cases of Bladder Cancer in Germany (2017–2030)
Table 13: Diagnosed Prevalent cases of Bladder Cancer in Germany (2017–2030)
Table 14: Diagnosed Prevalent cases of NMIBC in Germany (2017–2030)
Table 15: Age-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Table 16: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Table 17: Grade-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Table 18: Risk-specific Diagnosed Prevalence of NMIBC in Germany (2017–2030)
Table 19: Prevalent cases of Bladder Cancer in France (2017–2030)
Table 20: Diagnosed Prevalent cases of Bladder Cancer in France (2017–2030)
Table 21: Diagnosed Prevalent cases of NMIBC in Germany (2017–2030)
Table 22: Age-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Table 23: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Table 24: Grade-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Table 25: Risk-specific Diagnosed Prevalence of NMIBC in France (2017–2030)
Table 26: Prevalent cases of Bladder Cancer in Italy (2017–2030)
Table 27: Diagnosed Prevalent cases of Bladder Cancer in Italy (2017–2030)
Table 28: Diagnosed Prevalent cases of NMIBC in Italy (2017–2030)
Table 29: Age-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Table 30: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Table 31: Grade-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Table 32: Risk-specific Diagnosed Prevalence of NMIBC in Italy (2017–2030)
Table 33: Prevalent cases of Bladder Cancer in Spain (2017–2030)
Table 34: Diagnosed Prevalent cases of Bladder Cancer in Spain (2017–2030)
Table 35: Diagnosed Prevalent cases of NMIBC in Spain (2017–2030)
Table 36: Age-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Table 37: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Table 38: Grade-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Table 39: Risk-specific Diagnosed Prevalence of NMIBC in Spain (2017–2030)
Table 40: Prevalent cases of Bladder Cancer in the United Kingdom (2017–2030)
Table 41: Diagnosed Prevalent cases of Bladder Cancer in the UK (2017–2030)
Table 42: Diagnosed Prevalent cases of NMIBC in the UK (2017–2030)
Table 43: Age-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Table 44: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Table 45: Grade-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Table 46: Risk-specific Diagnosed Prevalence of NMIBC in the UK (2017–2030)
Table 47: Prevalent cases of Bladder Cancer in Japan (2017–2030)
Table 48: Diagnosed Prevalent cases of Bladder Cancer in Japan (2017–2030)
Table 49: Diagnosed Prevalent cases of NMIBC in Japan (2017–2030)
Table 50: Age-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Table 51: Tumor (T) stage-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Table 52: Grade-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)
Table 53: Risk-specific Diagnosed Prevalence of NMIBC in Japan (2017–2030)